# Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

> **NCT02229071** · PHASE1,PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 106 (actual)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Donafenib(200mg)
- **DRUG:** Donafenib(300mg)

## Key facts

- **NCT ID:** NCT02229071
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-12
- **Final completion:** 2016-10-30
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229071, "Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02229071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*